This “Myopia - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. Myopia occurs if the eyeball is too long or the cornea (the clear front cover of the eye) is too curved. As a result, the light entering the eye isn't focused correctly, and distant objects look blurred. While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop myopia. People with myopia can have difficulty clearly seeing a movie or TV screen, a whiteboard in school or while driving. Generally, myopia first occurs in school-age children. Because the eye continues to grow during childhood, it typically progresses until about age 20. However, myopia may also develop in adults due to visual stress or health conditions such as diabetes. Testing for myopia may use several procedures to measure how the eyes focus light and to determine the power of any optical lenses needed to correct the reduced vision. Glasses or contact lenses can correct myopia in children and adults. For adults only (with rare exceptions for children), there are several types of refractive surgeries that can also correct myopia.
"Myopia - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myopia pipeline landscape is provided which includes the disease overview and Myopia treatment guidelines. The assessment part of the report embraces, in depth Myopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve Myopia.
This segment of the Myopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MicroPine: Eyenovia
Atropine ophthalmic solution, known as MicroPine in US, is developed by Eyenovia, Inc. for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. It is designed based on Eyenovia's Optejet microdose formulation and delivery platform using its patented high-precision piezo-print technology known as MAP (microdose array print) to deliver 6-8 µL of drug, consistent with the capacity of the tear film of the eye. Microdose administration of the drug is anticipated to result in low systemic and ocular drug exposure while improving comfort and ease-of-use in children. Atropine micro-formulation licensed to Arctic vision in China, Hong Kong, Macau, Taiwan and South Korea. Atropine micro-formulation licensed to Bausch Health in USA and Canada. The atropine micro formulation is being evaluated in Phase III clinical trials.
There are approx. 6+ key companies which are developing the therapies for Myopia. The companies which have their Myopia drug candidates in the most advanced stage, i.e. Phase III include,Eyenovia.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myopia therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myopia drugs.
Geography Covered
- Global coverage
Myopia Understanding
Myopia: Overview
Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. Myopia occurs if the eyeball is too long or the cornea (the clear front cover of the eye) is too curved. As a result, the light entering the eye isn't focused correctly, and distant objects look blurred. While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop myopia. People with myopia can have difficulty clearly seeing a movie or TV screen, a whiteboard in school or while driving. Generally, myopia first occurs in school-age children. Because the eye continues to grow during childhood, it typically progresses until about age 20. However, myopia may also develop in adults due to visual stress or health conditions such as diabetes. Testing for myopia may use several procedures to measure how the eyes focus light and to determine the power of any optical lenses needed to correct the reduced vision. Glasses or contact lenses can correct myopia in children and adults. For adults only (with rare exceptions for children), there are several types of refractive surgeries that can also correct myopia.
"Myopia - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myopia pipeline landscape is provided which includes the disease overview and Myopia treatment guidelines. The assessment part of the report embraces, in depth Myopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve Myopia.
Myopia Emerging Drugs Chapters
This segment of the Myopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myopia Emerging Drugs
MicroPine: Eyenovia
Atropine ophthalmic solution, known as MicroPine in US, is developed by Eyenovia, Inc. for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. It is designed based on Eyenovia's Optejet microdose formulation and delivery platform using its patented high-precision piezo-print technology known as MAP (microdose array print) to deliver 6-8 µL of drug, consistent with the capacity of the tear film of the eye. Microdose administration of the drug is anticipated to result in low systemic and ocular drug exposure while improving comfort and ease-of-use in children. Atropine micro-formulation licensed to Arctic vision in China, Hong Kong, Macau, Taiwan and South Korea. Atropine micro-formulation licensed to Bausch Health in USA and Canada. The atropine micro formulation is being evaluated in Phase III clinical trials.
- NVK002; Nevakar
Myopia: Therapeutic Assessment
This segment of the report provides insights about the different Myopia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Myopia
There are approx. 6+ key companies which are developing the therapies for Myopia. The companies which have their Myopia drug candidates in the most advanced stage, i.e. Phase III include,Eyenovia.
Phases
This report covers around 6+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Myopia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myopia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myopia drugs.
Myopia Report Insights
- Myopia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Myopia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myopia drugs?
- How many Myopia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myopia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myopia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myopia and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Myopia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Myopia - Analytical Perspective
In-depth Commercial Assessment
- Myopia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Myopia Collaboration Deals
- Company-Company Collaborations (Licensing/Partnering) Analysis
- Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
MicroPine: Eyenovia
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II/III)
- Comparative Analysis
SYD-101: Sydnexis
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Myopia Key Companies
Myopia Key Products
Myopia- Unmet Needs
Myopia- Market Drivers and Barriers
Myopia- Future Perspectives and Conclusion
Myopia Analyst Views
Myopia Key Companies
AppendixList of Tables
Table 1 Total Products for Myopia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Myopia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Nevakar
- Eyenovia
- Sydnexis
- Santen Pharmaceutical
- Ocumension
- iVeena Delivery Systems